Drug Profile
INGN 231
Latest Information Update: 04 Mar 2008
Price :
$50
*
At a glance
- Originator Introgen Therapeutics
- Class Antineoplastics; Gene therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 08 Apr 2003 No development reported - Preclinical for Prostate cancer in USA (unspecified route)
- 19 Jun 2001 INGN 231 is in active development
- 13 Nov 1997 Preclinical development for Prostate cancer in USA (Unknown route)